HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: fj.07-098954v1 22/7/2465    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Shimizu, H. Articles by Morishita, R. PubMed PubMed Citation Articles by Shimizu, H. Articles by Morishita, R.

Angiotensin II accelerates osteoporosis by activating osteoclasts

Hideo Shimizu^*,,1, Hironori Nakagami^,1, Mariana Kiomy Osako^*, Rie Hanayama^*, Yasuo Kunugiza, Takuji Kizawa, Tetsuya Tomita, Hideki Yoshikawa, Toshio Ogihara and Ryuichi Morishita^*,2

^* Division of Clinical Gene Therapy,

Department of Geriatric Medicine,

Division of Gene Therapy Science, and

Department of Orthopedic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan

²Correspondence: Division of Clinical Gene Therapy, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan. E-mail: morishit{at}cgt.med.osaka-u.ac.jp

Recent clinical studies suggest that several antihypertensive drugs, especially angiotensin-converting enzyme inhibitors, reduced bone fractures. To clarify the relationship between hypertension and osteoporosis, we focused on the role of angiotensin II (Ang II) on bone metabolism. In bone marrow-derived mononuclear cells, Ang II (1x10^–6 M) significantly increased tartrate-resistant acid phosphatase (TRAP) -positive multinuclear osteoclasts. Of importance, Ang II significantly induced the expression of receptor activator of NF-B ligand (RANKL) in osteoblasts, leading to the activation of osteoclasts, whereas these effects were completely blocked by an Ang II type 1 receptor blockade (olmesartan) and mitogen-activated protein kinase kinase inhibitors. In a rat ovariectomy model of estrogen deficiency, administration of Ang II (200 ng/kg/min) accelerated the increase in TRAP activity, accompanied by a significant decrease in bone density and an increase in urinary deoxypyridinoline. In hypertensive rats, treatment with olmesartan attenuated the ovariectomy-induced decrease in bone density and increase in TRAP activity and urinary deoxypyridinoline. Furthermore, in wild-type mice ovariectomy with five-sixths nephrectomy decreased bone volume by microcomputed tomography, whereas these change was not detect in Ang II type 1a receptor-deficient mice. Overall, Ang II accelerates osteoporosis by activating osteoclasts via RANKL induction. Blockade of Ang II might become a novel therapeutic approach to prevent osteoporosis in hypertensive patients.—Shimizu, H., Nakagami, H., Osako, M. K., Hanayama, R., Kunugiza, Y., Kizawa, T., Tomita, T., Yoshikawa, H., Ogihara, T., Morishita, R. Angiotensin II accelerates osteoporosis by activating osteoclasts.

Key Words: hypertension • renin-angiotensin system • RANKL • ARB • TRAP activity